Grail tumbles after cancer‑detection test fails in large study

Grail

20/02/2026 11:30

** Shares of cancer test maker Grail GRAL.O fall 52% to $49 premarket

** Co says its test for early cancer detection failed in large study

** Says main result of trial was not statistically significant but favorable trend was observed over time

** GRAL says it already sells the test called Galleri and has applied for FDA approval

** The Galleri trial is run with England's National Health Service and uses blood test aiming to detect cancers early by spotting DNA shed by tumors into bloodstream, GRAL says

** Stock up ~68% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))